Word

ATVEY

Status

Pending

Status Code

731

Status Date

Wednesday, April 3, 2024

Serial Number

97348838

Mark Type

4000

Filing Date

Wednesday, April 6, 2022

Published for Opposition

Tuesday, February 28, 2023

Trademark Owner History

TEVA PHARMACEUTICALS USA, Inc. - Owner At Publication

Classifications

5 Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; Pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Trademark Events

Apr 4, 2024

Notice Of Approval Of Extension Request E-Mailed

Apr 3, 2024

Sou Extension 2 Granted

Apr 3, 2024

Sou Extension 2 Filed

Apr 3, 2024

Sou Teas Extension Received

Oct 21, 2023

Notice Of Approval Of Extension Request E-Mailed

Oct 19, 2023

Sou Extension 1 Granted

Oct 19, 2023

Sou Extension 1 Filed

Oct 19, 2023

Sou Teas Extension Received

Apr 25, 2023

Noa E-Mailed - Sou Required From Applicant

Feb 28, 2023

Official Gazette Publication Confirmation E-Mailed

Feb 28, 2023

Published For Opposition

Feb 8, 2023

Notification Of Notice Of Publication E-Mailed

Jan 25, 2023

Approved For Pub - Principal Register

Jan 25, 2023

Examiner's Amendment Entered

Jan 25, 2023

Notification Of Examiners Amendment E-Mailed

Jan 25, 2023

Examiners Amendment E-Mailed

Jan 25, 2023

Examiners Amendment -Written

Jan 24, 2023

Assigned To Examiner

Apr 11, 2022

New Application Office Supplied Data Entered

Apr 9, 2022

New Application Entered